AR093341A1 - Antigenos vacunales quimericos contra el virus de la hepatitis c - Google Patents

Antigenos vacunales quimericos contra el virus de la hepatitis c

Info

Publication number
AR093341A1
AR093341A1 ARP130104019A ARP130104019A AR093341A1 AR 093341 A1 AR093341 A1 AR 093341A1 AR P130104019 A ARP130104019 A AR P130104019A AR P130104019 A ARP130104019 A AR P130104019A AR 093341 A1 AR093341 A1 AR 093341A1
Authority
AR
Argentina
Prior art keywords
virus
antigens
chimeric
chemical
against hepatitis
Prior art date
Application number
ARP130104019A
Other languages
English (en)
Inventor
Amador Caizares Yalena
Alvarez-Lajonchere Ponce De Leon Liz
Martinez Donato Gillian
Gonzalez Blanco Sonia
Aguilar Noriega Daylen
Dueas Carrera Santiago
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of AR093341A1 publication Critical patent/AR093341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente describe antígenos vacunales quiméricos contra el virus de la hepatitis C (VHC) que comprenden regiones seleccionadas de diferentes antígenos de dicho virus, las que se ubican en un orden determinado dentro del polipéptido. Dichos antígenos quiméricos, además, pueden incluir epitopos específicos para linfocitos T auxiliadores, diseñados de forma artificial. Los antígenos quiméricos, así como las composiciones vacunales resultantes, son aplicables a la esfera de la medicina y la industria farmacéutica, y tienen un uso profiláctico y/o terapéutico contra el VHC. Las composiciones vacunales generan una respuesta inmune potente y de amplio espectro contra diferentes antígenos de dicho virus, con un mínimo de componentes.
ARP130104019A 2012-11-05 2013-11-04 Antigenos vacunales quimericos contra el virus de la hepatitis c AR093341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
AR093341A1 true AR093341A1 (es) 2015-06-03

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104019A AR093341A1 (es) 2012-11-05 2013-11-04 Antigenos vacunales quimericos contra el virus de la hepatitis c

Country Status (15)

Country Link
US (1) US9676825B2 (es)
EP (1) EP2915544B1 (es)
JP (1) JP6259831B2 (es)
KR (1) KR102093495B1 (es)
CN (1) CN104837498B (es)
AR (1) AR093341A1 (es)
AU (1) AU2013339846B2 (es)
CA (1) CA2901346C (es)
CU (1) CU24112B1 (es)
ES (1) ES2644801T3 (es)
IN (1) IN2015DN03925A (es)
MX (1) MX358507B (es)
RU (1) RU2639504C2 (es)
WO (1) WO2014067498A1 (es)
ZA (1) ZA201503036B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
EP3515483A4 (en) * 2016-09-21 2020-12-16 The Governors of the University of Alberta HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
CA3061326A1 (en) 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
CA3093314A1 (en) 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2391843C (en) * 1999-11-19 2011-10-18 Csl Limited Hcv vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EP1981537B1 (en) * 2006-01-04 2015-08-26 GlaxoSmithKline Biologicals S.A. HCV E1E2 MF59-adjuvanted protein plus HCV E1E2 encoding alphavirus vector for eliciting HCV-specific T cells.
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
JP2012503011A (ja) * 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
ZA201503036B (en) 2016-01-27
MX2015005651A (es) 2015-08-20
KR20150079694A (ko) 2015-07-08
JP6259831B2 (ja) 2018-01-10
MX358507B (es) 2018-08-22
US20150307558A1 (en) 2015-10-29
US9676825B2 (en) 2017-06-13
CN104837498A (zh) 2015-08-12
KR102093495B1 (ko) 2020-03-26
CU24112B1 (es) 2015-08-27
RU2639504C2 (ru) 2017-12-21
EP2915544B1 (en) 2017-08-09
EP2915544A1 (en) 2015-09-09
IN2015DN03925A (es) 2015-10-02
WO2014067498A1 (es) 2014-05-08
JP2015536936A (ja) 2015-12-24
CN104837498B (zh) 2018-05-18
AU2013339846B2 (en) 2017-08-17
CA2901346A1 (en) 2014-05-08
RU2015121429A (ru) 2016-12-27
ES2644801T3 (es) 2017-11-30
AU2013339846A1 (en) 2015-05-14
CA2901346C (en) 2019-04-23
CU20120153A7 (es) 2014-06-27

Similar Documents

Publication Publication Date Title
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CU20180062A7 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
UY37456A (es) Inmunoglobulinas y sus usos
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR093341A1 (es) Antigenos vacunales quimericos contra el virus de la hepatitis c
MX2019005102A (es) Poxvirus quimericos sinteticos.
IL262514A (en) Pharmaceutical preparations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX2019007924A (es) Vacunas contra la influenza.
WO2015149016A3 (en) Breast and ovarian cancer vaccines
WO2014152271A8 (en) Viral proteins as immunomodulatory agents and vaccine components
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano

Legal Events

Date Code Title Description
FB Suspension of granting procedure